Neurofibromatosis type 2 (NF2): management
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Neurofibromatosis type 2 (NF2): management. Neurosurgeon, Otolaryngologist, Audiologist, Neurologist. Fully referenced neurology checklist.
Multidisciplinary management team
- Neurosurgeon
- Otolaryngologist
- Audiologist
- Neurologist
- Ophthalmologist
- Neuro-radiologist
- Neuro-oncologist
- Geneticist
Surgical treatment
Locked: subscribe to see this section.
Bevacizumab therapy: indications
Locked: subscribe to see this section.
Investigational drugs
Locked: subscribe to see this section.
Synonym
Locked: subscribe to see this section.
References
- Evans DGR, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res 2017; 23:e54-e61.
- Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33:1046-1052.
- Farschtschi S, Merker VL, Wolf D, et al. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand 2016; 133:475-480.
- Morris KA, Afridi SK, Evans DG, et al; on behalf of the UK NF2 Research Group. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis type 2. J Neurosurg Spine 2016; 16:1-9.
- Alanin MC, Klausen C, Caye-Thomasen P, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2-a retrospective case series. Int J Neurosci 2015; 26:1002-1006.
- And 4 more. Subscribe to see the full list
